secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001193125-26-053035
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion receives positive FDA feedback for CYC-126 Phase 2 POC study in TRD; remains on track for 2H 2026 initiation
--------------------------------------------------------------------------------

- Received positive pre-IND written feedback from FDA supporting CYC-126 Phase 2 POC study design in treatment-resistant depression (TRD).
- Remains on track to initiate Phase 2 POC study in 2H 2026; first patient in Australia, U.S. enrollment in 1H 2027.
- Formed Clinical Advisory Board with five key leaders in neuropsychiatry, anesthesiology, and clinical development.
- Selected contract research organization to support multinational study execution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000119312526053035/0001193125-26-053035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000119312526053035/d104475d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-053035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer